Get the Stockscreener App
2.53
4.55%
0.11
After Hours:
2.48
-0.05
-1.98%
Spero Therapeutics Inc stock is traded at $2.53, with a volume of 617.27K.
It is up +4.55% in the last 24 hours and down -3.07% over the past month.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$2.42
Open:
$2.47
24h Volume:
617.27K
Relative Volume:
1.57
Market Cap:
$146.49M
Revenue:
$59.62M
Net Income/Loss:
$8.57M
P/E Ratio:
21.26
EPS:
0.119
Net Cash Flow:
$-12.62M
1W Performance:
+0.00%
1M Performance:
-3.07%
6M Performance:
+5.86%
1Y Performance:
+328.81%
1-Day Range:
$2.44
$2.565
1-Week Range:
$2.41
$2.63
52-Week Range:
$0.57
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Name
Spero Therapeutics Inc
Sector
Industry
Phone
857-242-1600
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.53 | 140.12M | 59.62M | 8.57M | -12.62M | 0.119 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-23-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-01-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Initiated | Evercore ISI | Outperform |
| Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-19 | Initiated | Janney | Buy |
| Feb-09-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-27-17 | Initiated | BofA/Merrill | Neutral |
| Nov-27-17 | Initiated | Oppenheimer | Outperform |
| Nov-27-17 | Initiated | Stifel | Buy |
View All
Spero Therapeutics Inc Stock (SPRO) Latest News
No call planned as Spero sets May 13 for Q1 results update - Stock Titan
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - GlobeNewswire
MSN Money - MSN
SPRO Stock Price, Quote & Chart | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short Interest - MarketBeat
Best Momentum Stock to Buy for October 10th - MSN
Spero Therapeutics (NASDAQ: SPRO) 2026 proxy adds stock increase and new incentive plan - Stock Titan
Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN
SPRO Forecast, Price Target & Analyst Ratings | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
ROSEN, Top Ranked Investor Counsel, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionSPRO - TMX Newsfile
Spero Therapeutics (SPRO) Stock Volume Spike Alert (Builds on Momentum) 2026-04-20Open Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
Spero Therapeutics (SPRO) Stock Insider Buying (Market Focus) 2026-04-18Algo Picks - Cổng thông tin điện tử tỉnh Lào Cai
Spero Therapeutics Stock Rises Above 50-Day Moving Average - National Today
Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Spero Therapeutics (NASDAQ: SPRO) asks shareholders to double authorized shares to 240M - Stock Titan
Portfolio Shifts: Is Spero Therapeutics Inc stock showing strong momentum2026 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
MACD Signal: Does Spero Therapeutics Inc have pricing power2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
Can Spero Therapeutics (SPRO) Stock increase dividends | Price at $2.63, Down 5.40%Social Trading Insights - Newser
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
Is Spero Therapeutics (SPRO) Stock undervalued by the market | Price at $2.73, Up 0.55%Expert Verified Trades - Newser
Market Overview: Will Spero Therapeutics Inc benefit from seasonality2026 Pullbacks & Capital Efficiency Focused Ideas - baoquankhu1.vn
Market Review: What is the PEG ratio of Spero Therapeutics IncInflation Watch & Safe Capital Growth Stock Tips - baoquankhu1.vn
Is Spero Therapeutics (SPRO) Stock Reacting to Market | Price at $2.73, Up 2.43%Crowd Risk Alerts - Newser
Spero Therapeutics Stock Rises Above 50-Day Average - National Today
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Is Spero Therapeutics (SPRO) Stock Growing Now | Price at $2.54, Up 4.32%Certified Trade Ideas - Newser
Spero Therapeutics Secures Financial Stability Through 2028 () - aktiencheck.de
SPRO Stock Analysis: Spero Therapeutics Inc. Biotech Play at $2.43 Post Minor Daily Dip - Newser
Spero Therapeutics (NASDAQ:SPRO) Upgraded by Wall Street Zen to "Strong-Buy" Rating - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) versus Mereo BioPharma Group (NASDAQ:MREO) Financial Contrast - Defense World
Spero Therapeutics (SPRO) Earnings Turn Positive Challenging Bearish Profitability Narratives - Sahm
Spero Therapeutics shares jump over 4% on better-than-expected Q4 print - Investing.com
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update - Bitget
Spero Therapeutics earnings beat by $0.73, revenue topped estimates - Investing.com Canada
SPERO THERAPEUTICS ($SPRO) Releases Q4 2025 Earnings - Quiver Quantitative
Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Estimates By $0.73 EPS - MarketBeat
Spero Therapeutics Q4 revenue nearly triples, swings to profit - TradingView
Spero Therapeutics 2025 10-K: $66.8M Revenue, $0.15 EPS - TradingView
Spero Therapeutics (NASDAQ: SPRO) turns 2025 profit as tebipenem advances - Stock Titan
BRIEF-Spero Therapeutics Q4 EPS USD 0.56 - TradingView
[10-K] Spero Therapeutics, Inc. Files Annual Report - Stock Titan
Can Spero Therapeutics Inc sustain earnings growth2026 Macro Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround - MSN
Analyst Calls: Is Spero Therapeutics Inc stock showing strong momentumWeekly Gains Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
If You Invested $1,000 in Spero Therapeuti (SPRO) - Stock Titan
Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Spero Therapeutics (SPRO.US) will release its earnings report after the market closes on March 26. - 富途牛牛
Activity Recap: Is Spero Therapeutics Inc stock showing strong momentumPortfolio Gains Summary & Fast Gain Stock Tips - baoquankhu1.vn
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 - The Manila Times
Spero Therapeutics (SPRO) Expected to Announce Earnings on Thursday - MarketBeat
Spero Therapeutics Inc 預計每股虧損 55 美分財報前瞻 - TradingView
Spero Therapeutics Inc Stock (SPRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):